Home > English articles

English articles

In this section English articles are published on neuropathy.

Hacking into chronic painstates with the endocannabinoid palmitoylethanolamide

Palmitoylethanolamide (brandnames een PEA-houdend product and PeaPure) is now registered as a supplement in various European countries and is one of the major existing new non-ionchannel tools to target the glia and the neurons in neuropathic and chronic pain. The availability of this compound leads to this discussion on how to influence chronic pain states with this endocannabinoid.

Chronic pain can disrupt brain function and cause many somatic and psychological problems. When neurons fire too much they may change their connections with other neurons and may even die. Crucial to understanding chronic pain are insights in the function of neuronal networks and the role of the all-invading glia cells. But: ‘Glia are nervous system caretakers whose nurturing can go too far. 

Lees meer...

Neuronal damage leads to increase production palmitoylethanolamide and other endocannabinoids

Neuronal damage as assessed by transection of long-range projections apparently provides a strong time-dependent and area-confined signal for de novo synthesis of various endocannabinoids, presumably to restrict neuronal damage. In an elegant study Sonja Kallendrusch and colleagues pointed out some recent studies demonstrating the neuroprotective properties of endocannabinoids in various models of neuronal lesion in vitro and in vivo. Palmitoylethanolamide, they emphesised, mediates its neuroprotective effects via dual PPAR alpha activation on microglial cells and neurons.

Lees meer...

PeaPure: some differences and similarities

PeaPure: we will discuss some differences and similarities of these three nutraceuticals. Palmitoylethanolamide is the active ingredient in all three. een PEA-houdend product is the Italian branded nutraceutical, available in Italy probably since 2007. een PEA-houdend product was developed since the end of last year, and the name een PEA-houdend product refers to the normalization of mast cell hyperactvity. The brandname een PEA-houdend product has been created in 2005.

een PEA-houdend product is the brand name of the in Italy produced palmitoylethanolamide version, een PEA-houdend product consists of 400 and 200 mg tablets, and PeaPure is a brand introduced in 2012 by the company Russell Science Ltd, produced in the Netherlands.


Lees meer...

Johnson & Johnson work on glutamate as a target for neuropathic pain

Johnson & Johnson work on glutamate as a target for neuropathic pain and in 2009 researchers from Belgium published their understanding about the role of the glutamate receptor in neuropathic hypersensitivity.

Lees meer...

AM1241, a Canabinoid ligand against cancer pain

Cannabis is an age-old analgesic which we use off and on for the treatment of severe neuropathic pain, as an adjunct to other treatment modalities. Now, a new study demonstrates the putative positive effect of  a new Cannabinoid CB(2) agonists , AM1241.

Lees meer...

Integrated Medicine concept for the treatment of neuropathic pain

Research over the last few decades has shown an increased use of complementary and alternative therapies (CAM) and an integration of aspects of CAM into mainstream medical treatment, health care organisations and insurance plans.  It has been shown that the process of care may be as important as the outcomes of treatment, which may explain in part the relatively large popularity of CAM for many patients on a world wide base. (Muir Gray JA. Evidence-Based Healthcare. How to Make Health Policy and Management Decisions. 2. London: Churchill Livingstone; 2001) 

Lees meer...

Neuropathic pain: what is it?

Neuropathic pain is defined as “Pain initiated or caused by a primary lesion or dysfunction in the nervous system”. Neuropathic pains are divided into peripheral neuropathic pain due to lesion of the peripheral nervous system and central pain following lesions of the central nervous system.

Lees meer...

ALGRX 4975 (Johns Hopkins University)

ALGRX 4975 (Johns Hopkins University) is under development in neuropathic pain, in phase II.

Lees meer...

Burning feet and neuropathy

In neuropathy and neuropathic pain patients can be suffering much from burning feet. Whatever the try, the burning and stinging sensations do not waver. The bruning sensations, the sensations of hot and painful feet  is due to damage to the nerves, in this case the long nerves from your spinal cord to your feet. In some cases, the burning feet may be so painful that you cannot sleep anymore.

Lees meer...

Annual Cost of diabetic neuropathy: circa $4000

The health care costs associated diabetic polyneuropathy in patients range from $1,600 to $7,000 per case each year. As the incidence of neuropathy is expected to rise as the result of an increasing older population at elevated risk diabetes, the overall costs will rise. Here a press release on the costs for neuropathy, dated 27 April 2010, released by the American Pain Society.

Lees meer...

MDA19: pharmacological profile of cannabinoid ligand

The cannabinoid receptor 2 (CB(2)) agonists are potential therapeutic targets in the treatment of neuropathic pain. The pharmacological profile of  N’-[(3Z)-1-(1-hexyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide (MDA19), a CB(2) agonist suggest MDA19 could be a analgesic for the treatment of neuropathic pain.

Lees meer...

Nerve cell regeneration and the receptor called DCC (Deleted in Colorectal Carcinoma)

Researchers from the university of Montreal published in Cell an article that gives some new insight in the issue of nerve cell regeneration. "We found an alternate way that helps nerve cells respond quickly and locally," sayd one of the authors of the paper, Philippe P. Roux, a professor of pathology and cell biology and a researcher at the University of Montreal Institute for Research in Immunology and Cancer (IRIC). He sees new therapeutic targets in future based on this principle:  "We can envisage manipulating this alternate mechanism to make cells respond locally to their environment. Our findings mean that scientists must consider a new way that cells organize themselves to perform essential functions."

Lees meer...

Motor cortex stimulation (MCS) for neuropathic pain

In the European Journal of Pain Supplements, 19 juli 2010 Garcia–Larrea discussed the value of Motor cortex stimulation (MCS), a relatively recent neurosurgical technique for pain control, in the treatment fo neuropathic pain. This is an abstract of a talk he gave at the  Third International Congress on Neuropathic Pain in Athens earlier this year. We were there and would like to make some commets, as this talk was discussed in great detail by a MD from the UK. She stated that there has not been conducted one methodological acceptable clinical trial analysing the safety and efficacy of this technique.

Lees meer...

MAG neuropathy

Here an entry from a patient’s blog with a description of a patient of what he experienced:

Lees meer...

What You Can’t Feel Can Hurt You

What You Can’t Feel Can Hurt You, the title of a crisp article on neuropathy and its consequences for our health. 

Lees meer...

Glia cells, abundant in the nervous system


Glia cells comprise 90% of the cells in the nervous system. The other 10% of cells consists of neurons. In the artist impression we see the high number of glia cells for each separate neuron.

The word ‘Glia’ is derived from the Greek word for "glue" giving the impression that the main function of these cells is to keep the brain from running out of our ears. (Bear M.F. Neuroscience, exploring the Brain 2007 3rd ed.)

Glia cells are thought to insulate, contribute and nourish neighbouring cells. Recently, more and more knowledge has been gained in the role of glia in neuropathic pain. Glia seems to play a much more important role than anticipated, hence the term ‘gliopathic pain’. Glial activation is required and sufficient for chronic pain sensitization, the root cause of neuropathic pain.

Lees meer...

CRPS type 1 and ketamine cream

crps-ketamine.jpg CRPS type 1 and ketamine cream:

Lees meer...

Pudendal neuralgia responding to a novel use of palmitoylethanolamide

Pudendal neuralgia is the most common and most disabling form of pelvic pain. It presents as unilateral or bilateral burning pain of the anterior or posterior perineum that is worse on sitting and relieved by standing, not usually associated with night pain.This pain is a cause of chronic, disabling, and often intractable perineal pain.

Lees meer...

Inflammatory bowel disease, mast cells and PEA

Neuroinflammation in inflammatory bowel disease, the titel of a leading article on the role of amongst others the mast cell in IBD. ( Journal of Neuroinflammation 2010, 7:37). We quote from this open access article several parts related to the impact of the mast cell on IBD. These quotations demonstrate that the use of the natural anti-inflammatory agent palmitoylethanolamide might be a very useful to treat patients suffering from these disorders.

In our clinic we saw a clear therapeutic effect when we prescribed PEA in a patient suffering from colitis ulcerosa combined with severe neuropathic pain. Not only was the neuropathic pain reduced in severeity by more than 50%, the same holds true for the symptoms of the IBD, diarrhoea and fecal incontinence.

Lees meer...

Ten year old paralysed King Charles spaniel runs again after palmitoylethanolamide!

een PEA-houdend product-spaniel.jpg Ten year old paralysed King Charles spaniel runs again after een PEA-houdend product! And no PSOM, no inflammed eyes anymore. Dose administered: 300 mg een PEA-houdend product granulate twice daily. 

After 6 months the dog was switched over to a new PEA product, PeaPure. The clinical reaction was even superior, probably due to the absence of pharmaceutical excipients. The dog walked better, longer and the mild eye inflammations under een PEA-houdend product treatment vanished totally and within 1 week. The now 11 year old dog is already 4 months stable on PeaPure, and nearly a year on PEA.  

Lees meer...

Intractable neuropathic pain in Diabetes treated with palmitoylethanolamide and topical cream

Case description

A 53 year old famale patient suffered from diabetes type II since more than 10 years. She developed severe pains at the age of 48 and was totally refractory for many analgesics. Prescription of gabapentine, amitriptyline, pregabalin and carbamazepine remained unsuccesful in reducing her pains. On the numeric rating scale (NRS) for pain she scored 8 over 10.

She was a candidate for a spinal cord stimulator and wished first to follow our treatment protocol for treatment-resistant neuropathic pains, based on palmitoylethanolamide ( PeaPure).

Lees meer...

Multimodal pain management, and the role of palmitoylethanolamide

As yet, no “gold standard” has emerged for multimodal pain management for neuropathic pain. The various multimodal pain protocols that have been developed, however, share similar objectives, to reduce side effects, to reduce dose and to avoid and even to eliminate narcotics leading to troublesome side-effects while reducing the quality of life. Because pain involves multiple mechanisms that rely  on different receptor systems, it is beneficial to utilize  a multimodal approach to achieve pain relief in complex pain states such as neuropathic pain. 

Lees meer...

New treatment algorithm for neuropathic pain

Treatment algorithms for the treatment of neuropathic pain are many, and mostly they follow the fashionable Cochrane approach and bring not a lot of news. The major problem with this approach is, that it does not work in practice. Treating patients with neuropathic pain is complicated and mostly we need a form of polypharmacy. 

Lees meer...

Painful legs and moving toes syndrome

Painful legs and moving toes syndrome, it really exist. And it is how it sounds. The legs start burning and aching, and the toes start moving on themselves. It is very uncommon, but it can be found. Neurologists found 14 cases of painful legs and moving toes (PLMT) syndrome out of 4,780 patients with movement disorders diagnosed at Mayo Clinic. So all these patients already suffered from one issue, a movement disorder, like Parkinson’s disease or dystonia.

Lees meer...

PRECISION TM Spinal Cord Stimulator (SCS) System

PRECISION TM Spinal Cord Stimulator (SCS) System : clinical studies forming the base of the registration of this device. Here a summary of the various studies supporting the registration of the precision spinal stimulator.

Lees meer...

Clinical trial methodology in neuropathic pain

The EMEA published a guideline on how to conduct studies in neuropathic pain, in 2007. It is worth while quoting from this guideline:

Lees meer...

AZD 2066 from AstraZeneca for neuropathic pain

AZD 2066 from AstraZeneca in phase II development for neuropathic pain.  Most probably it is a negative allosteric modulators of mGluR5 receptor. It might be discontinued, as there is only one trial reported to be finalized in 2008: AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers. A report in pubmed could not be identified.

Lees meer...

Trigeminus neuralgia treated with Gamma Knife surgery

Trigeminus neuralgia is difficult to treat. For those patients were medication such as carbamazepin is not helpful, the neurosurgeon can treat with the so called Gamma Knife…. 

Lees meer...

LinkedIn group Neuropathy and Neuropathic Pain for professionals

LinkedIn 4 neuropathic pain!

For all colleagues wanting to discuss on an international level how to treat neuropathic pain optimally and how to find better treatments, we have opened this brand new LinkedIn Group under the header: neuropathy and neuropathic pain. Please Join!!! 

More then 300 specialists in this group! 

The first international specialists, among which anesthesiologists, and neurologists, as well as prominent professors in these fields, have already joined directly after we opened this group. Within three week nearly 60 professionals. Within 3 months more then 300! From the USA, France, Spain, UK, Greece and the Netherlands. We gladly welcome these esteemed colleagues in our network.

Lees meer...

CNSB015 at Third International Congress on Neuropathic Pain in Athens, Greece

Relevare Pharmaceuticals Ltd. presented results for CNSB015 (flupirtine), at the Third International Congress on Neuropathic Pain on May 27 -30 in Athens, Greece, which we visited. Flupirtine belongs to the class of aminopyridines, like fampyridine used in MS, and is a centrally acting nonopioid analgesic. It is on the market in Europe since 1984 under the names Katadolon and Trancolong. It is a non-opioid, non-NSAID, non-steroidal analgesic. Flupirtine therefore is an already established clinical analgesic for musculoskeletal pain. 

Lees meer...